Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms
Manfredi Rizzo, Dragana Nikolić, Angelo Maria Patti, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2018) Vol. 1864, Iss. 9, pp. 2814-2821
Closed Access | Times Cited: 129

Showing 1-25 of 129 citing articles:

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
Adrian F. Hernandez, Jennifer B. Green, Salim Janmohamed, et al.
The Lancet (2018) Vol. 392, Iss. 10157, pp. 1519-1529
Open Access | Times Cited: 1481
Metabolic Syndrome: Updates on Pathophysiology and Management in 2021
Gracia Fahed, Laurence Aoun, Morgan Bou Zerdan, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 2, pp. 786-786
Open Access | Times Cited: 914
GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
Xin Zhao, Minghe Wang, Zhitong Wen, et al.
Frontiers in Endocrinology (2021) Vol. 12
Open Access | Times Cited: 253
COVID-19 and diabetes: The why, the what and the how
Sarah Cuschieri, Stephan Grech
Journal of Diabetes and its Complications (2020) Vol. 34, Iss. 9, pp. 107637-107637
Open Access | Times Cited: 148
Atherosclerosis Development and Progression: The Role of Atherogenic Small, Dense LDL
Jelena Vekić, Aleksandra Zeljković, Arrigo F.G. Cicero, et al.
Medicina (2022) Vol. 58, Iss. 2, pp. 299-299
Open Access | Times Cited: 79
Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Acute Coronary Syndrome: A Modern Cinderella?
Paschalis Karakasis, Nikolaos Fragakis, Κωνσταντίνος Κούσκουρας, et al.
Clinical Therapeutics (2024) Vol. 46, Iss. 11, pp. 841-850
Closed Access | Times Cited: 18
Physician Perceptions of the Safety and Efficacy of GLP-1 Receptor Agonists: Underestimation of Cardiovascular Risk Reduction and Discrepancies with Clinical Evidence
Srikanth Krishnan, Pratyaksh K. Srivastava, Jayram Attaluri, et al.
Journal of Cardiovascular Development and Disease (2025) Vol. 12, Iss. 1, pp. 19-19
Open Access | Times Cited: 2
The dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes
Jonathan M. Wilson, Amir Nikooienejad, Deborah Robins, et al.
Diabetes Obesity and Metabolism (2020) Vol. 22, Iss. 12, pp. 2451-2459
Open Access | Times Cited: 122
COVID-19 and diabetes management: What should be considered?
Antonio Ceriello, Anca Pantea Stoian, Manfredi Rizzo
Diabetes Research and Clinical Practice (2020) Vol. 163, pp. 108151-108151
Open Access | Times Cited: 111
Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimer’s and Parkinson’s disease therapeutics
Therese S. Salameh, Elizabeth M. Rhea, Konrad Talbot, et al.
Biochemical Pharmacology (2020) Vol. 180, pp. 114187-114187
Open Access | Times Cited: 106
Issues of Cardiovascular Risk Management in People With Diabetes in the COVID-19 Era
Antonio Ceriello, Eberhard Standl, Doina Catrinoiu, et al.
Diabetes Care (2020) Vol. 43, Iss. 7, pp. 1427-1432
Open Access | Times Cited: 81
Metabolic Syndrome-Related Kidney Injury: A Review and Update
Lirong Lin, Wei Beng Tan, Xianfeng Pan, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 65
Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease—Current Evidence
Emir Muzurović, Špela Volčanšek, Karin Zibar, et al.
Journal of Cardiovascular Pharmacology and Therapeutics (2022) Vol. 27
Open Access | Times Cited: 53
Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight and Cardiometabolic Parameters in Individuals With Obesity and Without Diabetes: A Systematic Review and Meta-Analysis
Huzaifa Ul Haq Ansari, Shurjeel Uddin Qazi, Faiza Sajid, et al.
Endocrine Practice (2023) Vol. 30, Iss. 2, pp. 160-171
Closed Access | Times Cited: 37
Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of tirzepatide
Fatemeh Taktaz, Rosaria Anna Fontanella, Lucia Scisciola, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 15
Targeting systemic inflammation in metabolic disorders. A therapeutic candidate for the prevention of cardiovascular diseases?
Elena Domingo, Patrice Marqués, Vera Francisco, et al.
Pharmacological Research (2024) Vol. 200, pp. 107058-107058
Open Access | Times Cited: 11
Metabolic dysfunction-associated fatty liver disease: current therapeutic strategies
Khamis Al-Hashmi, Rosaria Vincenza Giglio, Anca Pantea Stoian, et al.
Frontiers in Nutrition (2024) Vol. 11
Open Access | Times Cited: 10
Therapeutic Potential of Sodium-glucose Co-transporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists for Patients with Acute Coronary Syndrome: A Review of Clinical Evidence
Paschalis Karakasis, Dimitrios Patoulias, George Kassimis, et al.
Current Pharmaceutical Design (2024) Vol. 30, Iss. 27, pp. 2109-2119
Closed Access | Times Cited: 10
Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial
Lindsay E. Clegg, Robert C. Penland, Srinivas Bachina, et al.
Cardiovascular Diabetology (2019) Vol. 18, Iss. 1
Open Access | Times Cited: 71
Impact of Glucose-Lowering Medications on Cardiovascular and Metabolic Risk in Type 2 Diabetes
Angelo Maria Patti, Ali A. Rizvi, Rosaria Vincenza Giglio, et al.
Journal of Clinical Medicine (2020) Vol. 9, Iss. 4, pp. 912-912
Open Access | Times Cited: 51
Clinical Management of Diabetes Mellitus in the Era of COVID-19: Practical Issues, Peculiarities and Concerns
Chrysi Koliaki, Anastasios Tentolouris, Ioanna Eleftheriadou, et al.
Journal of Clinical Medicine (2020) Vol. 9, Iss. 7, pp. 2288-2288
Open Access | Times Cited: 51
Incretin Hormones in Obesity and Related Cardiometabolic Disorders: The Clinical Perspective
Joanna Michałowska, Ewa Miller‐Kasprzak, Paweł Bogdański
Nutrients (2021) Vol. 13, Iss. 2, pp. 351-351
Open Access | Times Cited: 49
Novel Therapeutical Approaches to Managing Atherosclerotic Risk
Rosaria Vincenza Giglio, Anca Pantea Stoian, Khalid Al‐Rasadi, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 9, pp. 4633-4633
Open Access | Times Cited: 42
Inclisiran: a small interfering RNA strategy targeting PCSK9 to treat hypercholesterolemia
Yajnavalka Banerjee, Anca Pantea Stoian, Arrigo F.G. Cicero, et al.
Expert Opinion on Drug Safety (2021) Vol. 21, Iss. 1, pp. 9-20
Closed Access | Times Cited: 42
An Update on the Current and Emerging Use of Thiazolidinediones for Type 2 Diabetes
Rosaria Vincenza Giglio, Νικόλαος Παπάνας, Ali A. Rizvi, et al.
Medicina (2022) Vol. 58, Iss. 10, pp. 1475-1475
Open Access | Times Cited: 37
Page 1 - Next Page

Scroll to top